Adrenocortical tumors have a distinct, long, non-coding RNA expression profile and LINC00271 is downregulated in malignancy.


Journal

Surgery
ISSN: 1532-7361
Titre abrégé: Surgery
Pays: United States
ID NLM: 0417347

Informations de publication

Date de publication:
01 2020
Historique:
received: 27 01 2019
revised: 28 03 2019
accepted: 16 04 2019
pubmed: 17 9 2019
medline: 6 5 2020
entrez: 17 9 2019
Statut: ppublish

Résumé

Adrenocortical carcinoma is an aggressive malignancy with a low but variable overall survival rate. The role of in adrenocortical carcinoma is poorly understood. Thus, in this study we performed long noncoding RNA expression profiling in adrenocortical carcinomas, adrenocortical adenomas, and normal adrenal cortex. Long noncoding RNA expression profile using Human LncRNA/mRNA Expression Microarray V3.0 (Arraystar, Inc, Rockville, MD) was analyzed in samples from 11 adrenocortical adenomas, 9 adrenocortical carcinomas, and 5 normal adrenal cortex. Differentially expressed long noncoding RNAs were validated using TaqMan, real-time quantitative polymerase chain reaction with additional samples. The dataset from the adrenocortical carcinoma Cancer Genome Atlas Programproject was used to evaluate the prognostic utility of long noncoding RNAs. Unsupervised hierarchical clustering showed distinct clustering of adrenocortical carcinoma samples compared with normal adrenal cortex and adrenocortical adenoma samples by long noncoding RNA expression profiles. A total of 874 long noncoding RNAs were differentially expressed between adrenocortical carcinoma and normal adrenal cortex. LINC00271 expression level was associated with prognosis, patients with low LINC00271 expression survived a shorter time than patients with high LINC00271 expression. Low LINC00271 expression was positively associated with WNT signaling, cell cycle, and chromosome segregation pathways. Adrenocortical carcinoma has a distinct long noncoding RNA expression profile. LINC00271 is downregulated in adrenocortical carcinoma and appears to be involved in biologic pathways commonly dysregulated in adrenocortical carcinoma.

Sections du résumé

BACKGROUND
Adrenocortical carcinoma is an aggressive malignancy with a low but variable overall survival rate. The role of in adrenocortical carcinoma is poorly understood. Thus, in this study we performed long noncoding RNA expression profiling in adrenocortical carcinomas, adrenocortical adenomas, and normal adrenal cortex.
METHODS
Long noncoding RNA expression profile using Human LncRNA/mRNA Expression Microarray V3.0 (Arraystar, Inc, Rockville, MD) was analyzed in samples from 11 adrenocortical adenomas, 9 adrenocortical carcinomas, and 5 normal adrenal cortex. Differentially expressed long noncoding RNAs were validated using TaqMan, real-time quantitative polymerase chain reaction with additional samples. The dataset from the adrenocortical carcinoma Cancer Genome Atlas Programproject was used to evaluate the prognostic utility of long noncoding RNAs.
RESULTS
Unsupervised hierarchical clustering showed distinct clustering of adrenocortical carcinoma samples compared with normal adrenal cortex and adrenocortical adenoma samples by long noncoding RNA expression profiles. A total of 874 long noncoding RNAs were differentially expressed between adrenocortical carcinoma and normal adrenal cortex. LINC00271 expression level was associated with prognosis, patients with low LINC00271 expression survived a shorter time than patients with high LINC00271 expression. Low LINC00271 expression was positively associated with WNT signaling, cell cycle, and chromosome segregation pathways.
CONCLUSION
Adrenocortical carcinoma has a distinct long noncoding RNA expression profile. LINC00271 is downregulated in adrenocortical carcinoma and appears to be involved in biologic pathways commonly dysregulated in adrenocortical carcinoma.

Identifiants

pubmed: 31522749
pii: S0039-6060(19)30548-3
doi: 10.1016/j.surg.2019.04.067
pmc: PMC6904435
mid: NIHMS1536934
pii:
doi:

Substances chimiques

Biomarkers, Tumor 0
RNA, Long Noncoding 0

Types de publication

Journal Article Observational Study Research Support, N.I.H., Intramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

224-232

Subventions

Organisme : Intramural NIH HHS
ID : ZIA BC011275-09
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Références

Cancer Cell. 2016 May 9;29(5):723-736
pubmed: 27165744
Nat Genet. 2014 Jun;46(6):607-12
pubmed: 24747642
Cancer Res. 2010 Nov 1;70(21):8276-81
pubmed: 20959480
Cancer. 2008 Dec 1;113(11):3130-6
pubmed: 18973179
Cancer Res. 2007 Jan 1;67(1):41-56
pubmed: 17210682
Eur J Cancer. 2013 Jul;49(11):2579-86
pubmed: 23561851
J Clin Endocrinol Metab. 2012 Jun;97(6):E1004-13
pubmed: 22472567
Genome Res. 2013 Feb;23(2):217-27
pubmed: 23132910
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
Genome Biol. 2014;15(12):550
pubmed: 25516281
Am J Surg Pathol. 1989 Mar;13(3):202-6
pubmed: 2919718
Ann Surg Oncol. 2010 Jan;17(1):263-70
pubmed: 19851811
Endocr Relat Cancer. 2015 Feb;22(1):99-109
pubmed: 25595289
Sci Rep. 2016 Nov 11;6:36973
pubmed: 27833134
Clin Cancer Res. 2009 Jan 15;15(2):668-76
pubmed: 19147773
Mol Oncol. 2014 Dec;8(8):1393-403
pubmed: 24954858
Mol Oncol. 2018 Nov;12(11):1980-2005
pubmed: 30216655
Int J Oncol. 2002 Jun;20(6):1161-5
pubmed: 12011993
Endocr Relat Cancer. 2009 Jun;16(2):573-83
pubmed: 19218281
Nat Genet. 2013 Oct;45(10):1134-40
pubmed: 24071852
Biochim Biophys Acta. 2012 Jul;1819(7):784-93
pubmed: 22426433
Genomics Proteomics Bioinformatics. 2016 Feb;14(1):42-54
pubmed: 26883671
Trends Cell Biol. 2014 Oct;24(10):594-602
pubmed: 25022466
Nucleic Acids Res. 2015 Oct 30;43(19):9327-39
pubmed: 26446994
N Engl J Med. 2012 Jun 7;366(23):2189-97
pubmed: 22551107

Auteurs

Floryne O Buishand (FO)

Center for Cancer Research, National Cancer Institute, Bethesda, MD; Department of Small Animal Surgery, Royal (Dick) School of Veterinary Studies, The University of Edinburgh, UK. Electronic address: Floryne.Buishand@ed.ac.uk.

Yi Liu-Chittenden (Y)

Center for Cancer Research, National Cancer Institute, Bethesda, MD.

Yu Fan (Y)

Computational Genomics and Bioinformatics Group, Center for Biomedical Informatics and Information Technology, National Cancer Institute, Rockville, MD.

Amit Tirosh (A)

Neuroendocrine Tumors Service, Endocrine Institute, Sheba Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Israel.

Sudheer K Gara (SK)

Center for Cancer Research, National Cancer Institute, Bethesda, MD.

Dhaval Patel (D)

Center for Cancer Research, National Cancer Institute, Bethesda, MD; Department of Surgery, Medical College of Wisconsin, Milwaukee, WI.

Daoud Meerzaman (D)

Computational Genomics and Bioinformatics Group, Center for Biomedical Informatics and Information Technology, National Cancer Institute, Rockville, MD.

Electron Kebebew (E)

Center for Cancer Research, National Cancer Institute, Bethesda, MD; Department of Surgery and Stanford Cancer Institute, Stanford University, CA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH